Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 20 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

5%

1 of 20 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
18(90.0%)
Phase 2
2(10.0%)
20Total
Phase 1(18)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (20)

Showing 20 of 20 trials
NCT05282940Phase 1Completed

Bioavailability of Levonorgestrel and Ethinyl Estradiol Tablets 15.0 mg/0.03 mg With Regards to Reference Product

Role: lead

NCT05349396Phase 1Completed

Bioavailability of Eszopiclone 3.0 mg With Regards to Reference Product

Role: lead

NCT05332106Phase 1Completed

Bioavailability of Estradiol Valerate and Dienogest 2 mg/2 mg With Regards to Reference Product

Role: lead

NCT05250141Phase 1Completed

Bioavailability of Levodopa 250 mg and Carbidopa 25 mg With Regards to Reference Product

Role: lead

NCT05158192Phase 1Completed

Bioavailability of Diosmin/Hesperidin (90/10) 500 mg Tablets With Regards to Reference Product

Role: lead

NCT05083325Phase 1Completed

Bioavailability of Oseltamivir Phosphate 75 mg With Regards to Reference Product

Role: lead

NCT04751318Phase 1Completed

Bioavailability of Duloxetine 60 mg With Regards to Reference Product in Feeding Conditions

Role: lead

NCT04723238Phase 1Completed

Bioavailability of Duloxetine 60 mg With Regards to Reference Product in Fasting Conditions

Role: lead

NCT04713904Phase 1Completed

Bioavailability of Clormadinone/Ethinyl Estradiol Tablets 2 mg/0.02 mg With Regards to Reference Product

Role: lead

NCT04194905Phase 1Completed

Bioavailability of Levonorgestrel/Ethinyl Estradiol Tablets 0.1 mg/0.02 mg With Regards to Reference Product

Role: lead

NCT04230070Phase 1Completed

Bioavailability of Levonorgestrel and Ethinyl Estradiol Tablets 15.0 mg/0.03 mg With Regards to Reference Product

Role: lead

NCT04440423Phase 1Completed

Bioavailability of Clotiazepam 5 mg With Regards to Reference Product

Role: lead

NCT04422028Phase 1Completed

Bioavailability of Desogestrel 0.075 mg Tablets With Regards to Reference Product

Role: lead

NCT04230083Phase 1Completed

Bioavailability of Dienogest 2.0 mg With Regards to Reference Product

Role: lead

NCT04193852Phase 1Completed

Bioavailability of Dienogest and Ethinyl Estradiol Tablets 2.0 mg/0.03 mg With Regards to Reference Product

Role: lead

NCT03967964Phase 1Completed

Pharmacokinetics of a Novel Vaginal Delivery System for Testosterone and Dehydroepiandrosterone (DHEA)

Role: lead

NCT02268032Phase 1Completed

Assess the Effect of Dehydroepiandrosterone (DHEA) or Other Androgenic Agents Over Markers of Ovarian Reserve

Role: lead

NCT02255045Phase 2Completed

Assessment of a Vaginal Ring With Meloxicam in the Treatment of Dysmenorrhea

Role: lead

NCT01839643Phase 1Completed

Assessment of a Vaginal Ring With Meloxicam on Ovarian Cycle in Fertile Women

Role: lead

NCT02225353Phase 2Completed

Efficacy Study of a Cervical Pessary Containing Progesterone for the Prevention of Preterm Delivery

Role: collaborator

All 20 trials loaded